Advances in menopausal therapy: The tissue-selective estrogen complex

Journal of the American Academy of Nurse Practitioners

Volumn 25, Issue 3, 2013, Pages 126-133

  Moore, Anne ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF NURSING   (United States)

Author keywords

Menopause; Osteoporosis; Therapies; Women's health

Indexed keywords

BAZEDOXIFENE; CONJUGATED ESTROGEN; ESTROGEN; INDOLE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; AGED; DRUG COMBINATION; ESTROGEN THERAPY; FEMALE; HUMAN; MENOPAUSE; MIDDLE AGED; PHASE 3 CLINICAL TRIAL (TOPIC);

ADULT; AGED; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; INDOLES; MENOPAUSE; MIDDLE AGED; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 84874542300     PISSN: 10412972     EISSN: 17457599     Source Type: Journal    
DOI: 10.1111/j.1745-7599.2012.00804.x     Document Type: Review

References (30)

1. Anderson, G. L., Chlebowski, R. T., Rossouw, J. E., Rodabough, R. J., McTiernan, A., Margolis, K. L., et al. (2006). Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas, 55, 103-115.
2. Archer, D. F., Dorin, M., Lewis, V., Schneider, D. L., & Pickar, J. H. (2001). Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertility and Sterility, 75, 1080-1087.
3. Archer, D. F., Lewis, V., Carr, B. R., Olivier, S., & Pickar, J. H. (2009). Bazedoxifene/conjugated estrogens (BZA/CE): Incidence of uterine bleeding in postmenopausal women. Fertility and Sterility, 92, 1039-1044.
4. Bachmann, G., Bobula, J., & Mirkin, S. (2010). Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. Climacteric, 13, 132-140.
5. Burger, G. H., & Teede, H. J. (2007). Endocrine changes during the perimenopause. In R. A. Lobo (Ed.), Treatment of the postmenopausal woman. Basic and clinical aspects (3rd ed., pp. 67-76). Burlington: Academic Press.
6. Davis, S. R., O'Neill, S. M., Eden, J., Baber, R., Ekangaki, A., Stocks, J. M., et al. (2004). Transition from estrogen therapy to raloxifene in postmenopausal women: Effects on treatment satisfaction and the endometrium-a pilot study. Menopause, 11, 167-175.
7. Hersh, A. L., Stefanick, M. L., & Stafford, R. S. (2004). National use of postmenopausal hormone therapy: Annual trends and response to recent evidence. Journal of the American Medical Association, 291, 47-53.
8. Kagan, R., Williams, R. S., Pan, K., Mirkin, S., & Pickar, J. H. (2010). A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens (BZA/CE) for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause, 17, 281-289.
9. Komm, B. S. (2008). A new approach to menopausal therapy: The tissue selective estrogen complex. Reproduction Science, 15, 984-992.
10. Komm, B. S., Kharode, Y. P., Bodine, P. V., Harris, H. A., Miller, C. P., & Lyttle, C. R. (2005). Bazedoxifene acetate: A selective estrogen receptor modulator with improved selectivity. Endocrinology, 146, 3999-4008.
11. Komm, B. S., & Lyttle, C. R. (2001). Developing a SERM: Stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Annals of New York Academy of Sciences, 949, 317-326.
12. Komm, B. S., & Pickar, J. H. (2006). Tissue selective estrogen complex (TSEC): A new paradigm for menopausal therapy. Complete Proceedings Collection of the 6th International Menopause Society Workshop. Menopause and Ageing, Quality of Life and Sexuality, Pisa, Italy, December 1-12.
13. Lindsay, R., & Cosman, F. (2007). Pathogenesis of osteoporosis. In R. A. Lobo (Ed.), Treatment of the postmenopausal woman. Basic and clinical aspects (3rd ed., pp. 323-330). Burlington: Academic Press.
14. Lindsay, R., Gallagher, J. C., Kagan, R., Pickar, J. H., & Constantine, G. (2009). Efficacy of tissue-selective estrogen complex (TSEC) of bazedoxifene/conjugated estrogens (BZA/CE) for osteoporosis prevention in at-risk postmenopausal women. Fertility and Sterility, 92, 1045-1052.
15. Lobo, R. A., Pinkerton, J. V., Gass, M. L. S., Dorin, M. H., Ronkin, S., Pickar, J. H., et al. (2009). Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic bone parameters and overall safety profile. Fertility and Sterility, 92, 1025-1038.
16. Miller, P. D., Chines, A. A., Christiansen, C., Hoeck, H. C., Kendler, D. L., Lewiecki, E. M., et al. (2008). Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. Journal of Bone and Mineral Research, 23, 525-535.
17. North American Menopause Society (2010). Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause, 17, 242-255.
18. Pickar, J. H. (2008). Tissue selective estrogen complex: A new paradigm for menopausal therapy. Menopausal Medicine, 16, S10-S13.
19. Pickar, J. H., Yeh, I.-T., Bachmann, G., & Speroff, L. (2009). Endometrial effects of a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertility and Sterility, 92, 1018-1024.
20. Pinkerton, J. V., Utian, W. H., Constantine, G. D., Olivier, S., & Pickar, J. H. (2009). Relief of vasomotor symptoms with the tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens: A randomized, controlled trial. Menopause, 16, 1116-1124.
21. Rolnick, S. J., Kopher, R. A., DeFor, T. A., & Kelley, M. E. (2005). Hormone use and patient concerns after the findings of the Women's Health Initiative. Menopause, 12, 399-404.
22. Silverman, S. L., Christiansen, C., Genant, H. K., Vukicevic, S., Zanchetta, J. R., De Villiers, T. J., et al. (2008). Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: Results from a 3-year, randomized, placebo- and active-controlled clinical trial. Journal of Bone and Mineral Research, 23, 1923-1934.
23. Stovall, D. W., Utian, W., Gass, M., Qu, Y., Muram, D., Wong, M., et al. (2007). The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. Menopause, 14, 510-517.
24. US Census Bureau (2008). Percent distribution of the projected population by selected age groups and sex for the United States: 2010 to 2050. Retrieved from http://www.census.gov/population/www/projections/summarytables.html.
25. Utian, W. H., Shoupe, D., Bachmann, G., Pinkerton, J. V., & Pickar, J. H. (2001). Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertility and Sterility, 75, 1065-1079.
26. Utian, W., Yu, H., Bobula, J., Mirkin, S., Olivier, S., & Pickar, J. H. (2009). Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women. Maturitas, 63, 329-335.
27. Van Duren, D., Ronkin, S., Pickar, J., & Constantine, G. (2006). Bazedoxifene combined with conjugated estrogens: A novel alternative to traditional home therapies. Fertility and Sterility, 86, S88-S89.
28. Warren, M. P. (2009). A tissue selective estrogen complex: A new horizon for menopausal symptoms. Menopause, 16, 1083-1084.
29. Women's Health Initiative Steering Committee (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial. Journal of the American Medical Association, 291, 1701-1712.
30. Writing Group for the Women's Health Initiative Investigators (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. Journal of the American Medical Association, 288, 321-333.